MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Psoriasis: Treatment and Pathogenesis
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,393 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,393 works in the cohort · of 4,299,418page 41 of 48

Labels cover 8 of 2,393 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,393 of 2,393 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Constance de la réponse selon les caractéristiques de sévérité de la maladie chez les patients atteints de psoriasis modéré à sévère traités par le guselkumab par rapport au sécukinumab : résultats de l’étude ECLIPSE à la semaine 48
M.P. Konstantinou, Richard G. Langley, Jamie Weisman, Antonio Martorell, Pablo Fernández‐Peñas, C.H. Hong +4 more
2019· article· fr· Annales de Dermatologie et de Vénéréologie· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affunlabeled
Potential Effects of Some Factors on Psoriasis Course in Children
Svetlana G. Gubanova, Eduard T. Ambarchyan, Leyla S. Namazova-Baranova, Еlena A. Vishneva, Irina V. Zelenkova, Viktor A. Gankovskiy +4 more
2024· article· en· Педиатрическая фармакология· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
049 Generalized pustular psoriasis (GPP) and palmoplantar pustulosis (PPP) both show upregulation of the IL-36, neutrophil chemokine, and innate pathways that are modulated by spesolimab, an anti-IL-36 receptor antibody, treatment
Patrick Baum, Sudha Visvanathan, Sandra Garcet, Janine Roy, Ralph A. Schmid, Sebastian Bossert +5 more
2020· article· en· Journal of Investigative Dermatology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affunlabeled
Safety of Long-Term Proactive Management with Fixed-Dose Combination Calcipotriene 0.005% and Betamethasone Dipropionate 0.064% Foam in Patients with Psoriasis Vulgaris: Results of a Phase III, Multicentre, Randomized, 52-Week, Vehicle-Controlled Trial
Mark Lebwohl, J.‐P. Lacour, Monika Liljedahl, Charles Lynde, Marie Holst Mørch, Diamant Thaçi +1 more
2020· article· en· SKIN The Journal of Cutaneous Medicine· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
affunlabeled
Determination of Knowledge of Patients Regarding Psoriasis
Maria Khalid, Rabia Ishfaq, Sana Younas, Komal Shehzade, Hasan Khalid, Qurat ul Ain Zulfi
2024· article· en· Journal of University Medical & Dental College· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations
aboutno affunlabeled
Deucravacitinib (Sotyktu)
CADTH
2023· article· en· Canadian Journal of Health Technologies· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
0
citations

How this was built: Screen · Findings · About